Amarin Corporation plc · NASDAQ:AMRN
Amarin — Technical Presentation (August 2011)
18 slides from Amarin's technical presentation, Aug 17, 2011
Slide 1: AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides: The MARINE Study
AMR101,, a Pure-EPA Omega-3 g Fatty y Acid, Lowers Triglycerides in Patients with Very y High g Triglycerides gy Without Raising LDL-C: The MARINE Study y HE Bays,1 CM Ballantyne,2 JJ Kastelein,3 E Stein,4 JL Isaacsohn,4 RA Braeckman,5 and PN Soni5 1Louisville, KY, USA; 2Houston, TX, USA; 3Amsterdam
Slide 2: Declaration of Interest
Declaration of Interest Dr. Bays reports research grants for the conduct of the MARINE study and other Amarin trials, and has served as an advisor to Amarin Pharma Inc. He has also received research grants from GlaxoSmithKline, Omthera, and Trygg, and in more than 20 years of clinical research resea
Slide 3: Introduction
Introduction • Fish oil therapies rich in OM-3 fatty acids (EPA and DHA) and fibrates effectively lower TG in hypertriglyceridemic patients; however, these agents may substantially increase LDL-C levels, especially in patients with very hi h TG llevels high l 1-3 13 • Pure EPA may reduce TG levels w
Slide 4: Objective
The MARINE Study Objective • The MARINE study (Multi-Center, PlAcebo-Controlled, Randomized, Double Double-BlINd, BlINd, 12 12-week week study with an open-label Extension) investigated the efficacy and safety of AMR101 in reducing TG levels in patients with very high TG (≥500 mg/dL) and evaluated t
Slide 5: Inclusion Criteria
The MARINE Study Inclusion Criteria • Men or women >18 years of age • Stable diet • No alterations in physical activity level during study • TG ≥500 mg/dL g and ≤2000 mg/dL g • If on background statin therapy, study participants were to remain on the same statin at the same dose through the duration
Slide 6: Study Design
The MARINE Study Study Design • 12-week, phase 3, multicenter study conducted in the US, South Africa, India, Ukraine, Finland, Germany, Italy, and Netherlands 4-6 Week 2-3 Week 12-Week 40-Week Lead-in Qualifying Double-Blind Period Open-Label Extension V3.1 (adjunct) AMR101 4 g/day 6 wks 1 wk 1 wk
Slide 7: Disposition of Patients
The MARINE Study Disposition of Patients 610 Patients Screened 381 (62.5%) Screen Failed: 333 Did not satisfy inclusion/exclusion criteria 32 Withdrew consent 5 Lost to follow-up 1 Protocol violation 3 Adverse event 229 Patients 7 Other Randomized AMR101 4 g/day AMR101 2 g/day Placebo Randomized 77
Slide 8: Baseline Characteristics
The MARINE Study Baseline Characteristics AMR101 AMR101 Placebo Total 4 g/day 2 g/day (n=76) (n=229) ( 77) (n=77) ( 76) (n=76) Age, mean y (SD) 51.9 (10.3) 53.4 (9.3) 53.4 (8.3) 52.9 (9.3) Age ≤65 y, n (%) 70 (90.9) 70 (92.1) 71 (93.4) 211 (92.1) Male, n (%) 59 (76.6) 58 (76.3) 58 (76.3) 175 (76.4)
Slide 9: Primary End Point
The MARINE Study Primary End Point • AMR101 significantly reduced median placebo- adjusted TG levels from baseline to study end – 4 g/day, 33.1% (P<0.0001) – 2 g/day g/day, 19 19.7% 7% (P=0 (P 0.0051) 0051) • Significant reductions in sub-populations – Patients with baseline TG >500 500 mg/dL – Pati
Slide 10: Median Percent Change (IQR) in TG from Baseline (ITT population)
The MARINE Study Median Percent Change (IQR) in TG from Baseline ((ITT p population) p ) 50 Treatment 4 g/day 40 2 g/day 30 Placebo 20 %) Median Change (% 10 0 -10 -20 -30 -40 0 1 2 3 4 5 6 7 8 9 10 11 12 Weeks of Treatment 10 ITT=intent-to-treat; IQR=interquartile range.
Slide 11: Change in Median Placebo-adjusted TG Levels by Baseline TG
The MARINE Study Change in Median Placebo-adjusted TG Levels from Baseline to Study y End by y Baseline TG ((ITT p population) p ) Baseline TG (mg/dL) ≤750 >750 All Patients 614 568 902 948 680 657 0 -5 4 g/day -10 2 g/day -9.1 -15 n=45 ange (%) NS -20 -19.7 Median Cha -25 n=73 -25.1 ** -30 n=48 ***
Slide 12: Change in Median Placebo-adjusted TG Levels by Statin Use
The MARINE Study Change in Median Placebo-adjusted TG Levels from Baseline to Study y End by y Statin Use ((ITT p population) p ) Baseline TG (mg/dL) With Statin No Statin All Patients 650 592 680 673 680 657 0 4 g/day -10 2 g/day -20 -16.4 ange (%) n=54 -19.7 * n=73 -30 -25.8 ** n=57 57 Median Cha
Slide 13: Median Placebo-Adjusted Change from Baseline for Efficacy End Points
The MARINE Study Median Placebo-Adjusted Change from Baseline for Efficacy y End Points ((ITT p population) p ) TG Non-HDL-C VLDL-C Lp- Apo B TC LDL-C HDL-C VLDL-TG hsCRP 10 PLA2 NS 5.2 NS 5 1.5 0 -5 5 -2.6 -2.3 NS 36 -3.6 NS n Change (%) -5.1 NS NS -6.8 -10 -8.1 -8.5 * * ** -10.1 NS -15 -13.6 -15.3
Slide 14: Change in Median Placebo-adjusted hsCRP Levels by Statin Use
The MARINE Study Change in Median Placebo-adjusted hsCRP Levels from Baseline to Study y End by y Statin Use ((ITT p population) p ) With Statin No Statin All Patients -2.7 4 g/day n=52 -10.1 2 g/day NS n=70 NS ange (%) -27.4 n=56 -33.2 33 2 Median Cha * -36.0 n=18 NS n=75 ** -67.9 n=19 ** **P<0.01;
Slide 15: Safety Assessments
The MARINE Study Safety Assessments • Treatment-emergent adverse events (TEAEs) similar across treatment groups – Most were mild to moderate and deemed not related to study drug • 2 SAEs deemed unrelated to studyy drug g – Noncardiac chest pain (AMR101 2 g/day) – Coronary artery disease (AMR101 4 g/
Slide 16: TEAEs Occurring in >3% of Patients (Safety Population)
The MARINE Study TEAEs Occurring in >3% of Patients (Safety Population) AMR101 AMR101 Placebo 4 g/day 2 g/day (n=76) (n=77) (n=76) Any y TEAE 27 ((35.1)) 26 ((34.2)) 28 ((36.8)) Diarrhea 1 (1.3) 4 (5.3) 5 (6.6) Nausea 1 (1.3) 5 (6.6) 4 (5.3) Eructation 0 1 (1.3) 3 (3.9) 16
Slide 17: Conclusions
The MARINE Study Conclusions • AMR101 (pure EPA) significantly reduced TG at both the 4 g/day and 2 g/day doses in patients with very high TG levels • AMR101 had no significant effect on LDL-C • AMR101 4 g/day significantly reduced non–HDL-C, Apo B, Lp-PLA2, TC, VLDL-C, VLDL-TG, and hsCRP, with no s
Slide 18: Thank You
Thank You 18